SCHEMBL29692191

SCHEMBL29692191

O=C(N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O)c1c(-c2ccccc2F)nn2ccc(N3CCOCC3)nc12

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 14/20 0.56
▸ CCKAR P32238 7/20 0.49
▸ CCKBR P32239 6/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23013981 1.00 CBLB (0.56) CBLBCCKARCCKBR
SCHEMBL23013186 0.94 CCKBR (0.51) CBLBCCKARCCKBR
SCHEMBL29692110 0.94 CCKBR (0.51) CBLBCCKARCCKBR
SCHEMBL29692237 0.85 NOTCH1 (0.43) CBLBCCKARCCKBR
SCHEMBL23013479 0.85 NOTCH1 (0.43) CBLBCCKARCCKBR
SCHEMBL30028727 0.85 CCKBR (0.55) CCKARCCKBR
SCHEMBL29939348 0.82 CCKBR (0.57) CCKARCCKBR
SCHEMBL28749202 0.79 CCKBR (0.54) CCKARCCKBR
SCHEMBL29692196 0.79 CCKBR (0.54) CCKARCCKBR
SCHEMBL23013932 0.79 CCKBR (0.56) CCKARCCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114555604-B Pharmaceutical compounds 辉瑞公司 2024-11-15 — — CN claimed
EP-4017856-A1 PHARMACEUTICAL COMPOUNDS Reviral Limited (GB) 2022-06-29 — — EP claimed
US-12227507-B2 Pharmaceutical compounds PFIZER INC. (US) 2025-02-18 — — US disclosed
US-11634425-B2 Pharmaceutical compounds PFIZER INC. (US) 2023-04-25 — — US disclosed
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-10-13 — — US disclosed
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-09-29 — — US disclosed
EP-4017856-A1 PHARMACEUTICAL COMPOUNDS Reviral Limited (GB) 2022-06-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12227507-B2 Pharmaceutical compounds CHRNA6, GABRA6, CHRNA7 CBLB 3268/4885CCKAR 199/4885CCKBR 488/4885
US-11634425-B2 Pharmaceutical compounds GABRA6, CHRNA6, CNR1 CBLB 2700/4885CCKAR 168/4885CCKBR 257/4885
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS CHRNA6, GABRA6, CHRNA7 CBLB 3268/4885CCKAR 199/4885CCKBR 488/4885
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS GABRA6, CNR1, CHRNA6 CBLB 3560/4885CCKAR 204/4885CCKBR 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback